1. Search Result
Search Result
Results for "

Topoisomerase IV, E. coli

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10581
    Gatifloxacin
    4 Publications Verification

    AM-1155; BMS-206584; PD135432

    Bacterial Topoisomerase Antibiotic Infection Neurological Disease Cancer
    Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic that can cross the blood-brain barrier, with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin
  • HY-10581A
    Gatifloxacin hydrochloride
    4 Publications Verification

    AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride
  • HY-E70898C

    Topoisomerase Metabolic Disease
    Topoisomerase IV, E. coli (EC 5.99.1.) is prepared by overexpressing the parC and parE subunits in E. coli. Topoisomerase IV is supplied as a heterotetramer complex in Dilution buffer.
    Topoisomerase IV, E. coli
  • HY-10581C

    AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate

    Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin sesquihydrate
  • HY-175539

    Bacterial Topoisomerase DNA/RNA Synthesis Infection
    DNA gyrase/Topo IV-IN-2 (Compound AK19) is an antibacterial agent with IC50 values of 0.783 μM and 7.136 μM against E. coli DNA gyrase and topoisomerase IV, respectively. DNA gyrase/Topo IV-IN-2 exhibits broad-spectrum antibacterial efficacy against both Gram-positive and Gram-negative pathogens. DNA gyrase/Topo IV-IN-2 can inhibit the biofilms of B. subtilis and MRSA, with an MIC of 1.9 μM against both B. subtilis and MRSA. DNA gyrase/Topo IV-IN-2 can be used in research related to anti-drug-resistant bacterial drugs .
    DNA gyrase/Topo IV-IN-2
  • HY-150044

    DNA/RNA Synthesis Topoisomerase Bacterial Infection
    Type II topoisomerase inhibitor 1 is a potent and selective E. coli DNA gyrase inhibitor (IC50: 1.7 nM), and forms hydrogen bonds with Asp73 residue. Type II topoisomerase inhibitor 1 inhibits topoisomerase IV activity (IC50: 0.98 μM). Type II topoisomerase inhibitor 1 can be used in the research of antibacterial area .
    Type II topoisomerase inhibitor 1
  • HY-10581B

    AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate

    Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin mesylate
  • HY-109785A

    Bacterial Infection
    (R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that disrupts supercoiling activity with an IC50 value of 3.3 µM. (R)-Gyramide A hydrochloride demonstrates antibacterial activity against E. coli, P. aeruginosa, and S. enterica (MICs of 10-80 µM). (R)-Gyramide A hydrochloride does not affect the closely related enzyme topoisomerase IV.
    (R)-Gyramide A hydrochloride
  • HY-10581AS

    AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride

    Isotope-Labeled Compounds Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin-d3 hydrochloride
  • HY-10581AR

    AM-1155 hydrochloride (Standard); BMS-206584 hydrochloride (Standard); PD135432 hydrochloride (Standard)

    Reference Standards Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (hydrochloride) (Standard) is the analytical standard of Gatifloxacin (hydrochloride). This product is intended for research and analytical applications. Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin hydrochloride (Standard)
  • HY-W700069

    AM-1155-d4; BMS-206584-d4; PD135432-d4

    Isotope-Labeled Compounds Antibiotic Bacterial Topoisomerase Infection
    Gatifloxacin-d4 (AM-1155-d4) is the deuterium labeled Gatifloxacin (HY-10581). Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50 = 13.8 μg/mL for S. aureus topoisomerase IV) and E.coli DNA gyrase (IC50 = 0.109 μg/mL) . Gatifloxacin can be used for the study of bacterial conjunctivitis in vivo.
    Gatifloxacin-d4
  • HY-10581R

    AM-1155 (Standard); BMS-206584 (Standard); PD135432 (Standard)

    Reference Standards Bacterial Topoisomerase Antibiotic Infection
    Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
    Gatifloxacin (Standard)
  • HY-10581CR

    AM-1155 sesquihydrate (Standard); BMS-206584 sesquihydrate (Standard); PD135432 sesquihydrate (Standard)

    Reference Standards Bacterial Topoisomerase Antibiotic Infection Inflammation/Immunology
    Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.
    Gatifloxacin sesquihydrate (Standard)
  • HY-E70899B

    Topoisomerase Metabolic Disease
    Topoisomerase IV, Pseudomonas aeruginosa (EC 5.99.1.) is prepared by overexpressing the subunits in E. coli. Topoisomerase IV is supplied as a heterotetramer complex in Dilution buffer.
    Topoisomerase IV, Pseudomonas aeruginosa
  • HY-E70899D

    Topoisomerase Others
    Topoisomerase IV, Acinetobacter baumannii (EC 5.99.1.) is prepared by overexpressing the subunits in E. coli. Topoisomerase IV is supplied as a heterotetramer complex in Dilution buffer.
    Topoisomerase IV, Acinetobacter baumannii
  • HY-E70899

    Topoisomerase Metabolic Disease
    Topoisomerase IV, Streptococcus pneumoniae (EC 5.99.1.) is prepared by overexpressing the subunits in E. coli.
    Topoisomerase IV, Streptococcus pneumoniae
  • HY-E70899A

    Topoisomerase Metabolic Disease
    Topoisomerase IV, Staphylococcus aureus (EC 5.99.1.) is prepared by overexpressing the subunits in E.coli.
    Topoisomerase IV, Staphylococcus aureus

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: